Improving Outcomes in Non-Hodgkin's:
Evidence-Based Best Practices
Evidence-Based Best Practices
Faculty: John P. Leonard, MD
(view biosketch)
(view biosketch)
Release Date: November 4, 2009
Learning Objectives:
- Discuss the molecular basis for the discrete sub-types of non-Hodgkin's lymphoma and how this knowledge provides
opportunities to risk stratify patients and customize treatment plans - Develop an algorithmic approach to treating patients with NHL according to national clinical guidelines
- Discuss clinical trial data results from new combinations of existing treatments and novel targeted therapies for NHL
Accreditation Statement:
The American Academy of Physician Education is accredited by the Institute for Medical Quality/California Medical Association
(IMQ/CMA) to provide continuing medical education for physicians. The American Academy of Physician Education takes
responsibility for the content, quality and scientific integrity of this CME activity.
Credit Designation Statement:
The American Academy of Physician Education designates this educational activity for a maximum of 2.0 hours AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may
also be applied to the CMA Certification in Continuing Medical Education.
The American Academy of Physician Education is accredited by the Institute for Medical Quality/California Medical Association
(IMQ/CMA) to provide continuing medical education for physicians. The American Academy of Physician Education takes
responsibility for the content, quality and scientific integrity of this CME activity.
Credit Designation Statement:
The American Academy of Physician Education designates this educational activity for a maximum of 2.0 hours AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may
also be applied to the CMA Certification in Continuing Medical Education.
Commercial Support: This activity is supported by an educational grant from Genentech.
Target Audience:
Oncologists, hematologists, radiologists, surgeons, internists, and other healthcare professionals interested in emerging
approaches to managing patients with NHL.
Oncologists, hematologists, radiologists, surgeons, internists, and other healthcare professionals interested in emerging
approaches to managing patients with NHL.